Zosano Pharma Corporation is a clinical-stage biopharmaceutical company. The Company is focused on providing systemic administration of therapeutics to patients using its ransdermal microneedle system (the System). The System is designed to facilitate drug absorption into the bloodstream. The Company’s lead product candidate is Qtrypta (M207). Qtrypta is a formulation of zolmitriptan delivered utilizing its System. Zolmitriptan is a serotonin receptor agonists known as triptans and is used as an acute treatment for migraine. Qtrypta is designed for absorption of zolmitriptan into the bloodstream without dependence on the gastrointestinal (GI) tract. Its same formulation, development name C213, is the treatment to provide relief for cluster headache.